company background image
T1CH34 logo

Bio-Techne BOVESPA:T1CH34 Stock Report

Last Price

R$15.44

Market Cap

R$70.7b

7D

1.3%

1Y

58.7%

Updated

22 Dec, 2024

Data

Company Financials +

Bio-Techne Corporation

BOVESPA:T1CH34 Stock Report

Market Cap: R$70.7b

T1CH34 Stock Overview

Develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. More details

T1CH34 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance1/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 53% below our estimate of its fair value

Earnings are forecast to grow 21.23% per year

Risk Analysis

Large one-off items impacting financial results

Profit margins (12.9%) are lower than last year (21.6%)


My Notes

Capture your thoughts, links and company narrative

Bio-Techne Corporation Competitors

Charles River Laboratories International

NYSE:CRL

US$9.5b

Eurofins Scientific

ENXTPA:ERF

€9.1b

Sartorius

XTRA:SRT3

€13.5b

Avantor

NYSE:AVTR

US$14.4b

Price History & Performance

Summary of share price highs, lows and changes for Bio-Techne
Historical stock prices
Current Share PriceUS$15.44
52 Week HighUS$16.38
52 Week LowUS$5.01
Beta1.27
1 Month Change14.88%
3 Month Change11.48%
1 Year Change58.68%
3 Year Change-29.82%
5 Year Changen/a
Change since IPO23.89%

Recent News & Updates

Recent updates

Shareholder Returns

T1CH34BR Life SciencesBR Market
7D1.3%0%0%
1Y58.7%0%0%

Return vs Industry: T1CH34 exceeded the BR Life Sciences industry which returned -4.7% over the past year.

Return vs Market: T1CH34 exceeded the BR Market which returned -11.7% over the past year.

Price Volatility

Is T1CH34's price volatile compared to industry and market?
T1CH34 volatility
T1CH34 Average Weekly Movementn/a
Life Sciences Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in BR Market0%
10% least volatile stocks in BR Market0%

Stable Share Price: Data is not available.

Volatility Over Time: Insufficient data to determine T1CH34's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19763,100Kim Keldermanwww.bio-techne.com

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.

Bio-Techne Corporation Fundamentals Summary

How do Bio-Techne's earnings and revenue compare to its market cap?
T1CH34 fundamental statistics
Market capR$70.74b
Earnings (TTM)R$916.86m
Revenue (TTM)R$7.13b

77.2x

P/E Ratio

9.9x

P/S Ratio

Is T1CH34 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
T1CH34 income statement (TTM)
RevenueUS$1.17b
Cost of RevenueUS$398.40m
Gross ProfitUS$773.19m
Other ExpensesUS$622.50m
EarningsUS$150.68m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.95
Gross Margin65.99%
Net Profit Margin12.86%
Debt/Equity Ratio14.0%

How did T1CH34 perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

34%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 18:49
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bio-Techne Corporation is covered by 27 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
James Francis MainwaringAtlantic Equities LLP
Catherine Ramsey SchulteBaird